Arrayit Corporation CEO updates shareholders

Arrayit Corporation (OTCBB: ARYC)

Letter to Shareholders from the CEO

October 7, 2009

With the start of trading of Arrayit Corporation (ARYC) on the bulletin board in March, 2009, we initiated a deliberate and measured strategy to introduce Arrayit's scientific accomplishments of the past 13 years to our shareholders. As we have laid the foundation for the announcement of future initiatives through this awareness campaign, we have seen interest in our stock steadily increase. After pioneering the development of research tools for genomics (the study of the genetic structure) and proteomics (the study of the proteins produced by the activity of specific genes), Arrayit is now entering the exciting field of diagnostics of disease states.

Our microarray based diagnostic kits for specific cancers and degenerative diseases are in the late stages of development. Arrayit has incorporated novel strategies that greatly improve the accuracy of the tests. Arrayit has demonstrated a unique ability to obtain consistent results where others have failed. In preparation for product launch, Arrayit Diagnostics, Inc. recently opened sales offices in Houston, Texas.

We are also pleased to report that our products are now represented by 44 international distributors with a presence in over 50 nations. For the third quarter of this year, sales are up 41% from a year ago. Our recently announced initiatives with the CDC, Sandia National Laboratory and the Parkinson's Institute are proceeding with remarkable results.

For 13 years we have positioned ourselves with a firm foundation of proven science and global success. We want to thank each of you for your ability to see the big picture and for being in a place to benefit from the contributions these diagnostic tests will make to alleviate personal suffering, and to provide much needed cost savings to the health care industry through early diagnosis and treatment.

Gene specific personalized treatments are in their infancy and with your continuing support, Arrayit will be a major contributor in helping the health care revolution mature.

Sincerely, Rene Schena CEO

SOURCE: Arrayit Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Survey reveals strong public desire for notification about AI use in healthcare